Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $231.77 | 11 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $149.71 | 7 | $0 (2024) |
| Alkermes, Inc. | $31.34 | 1 | $0 (2024) |
| Lundbeck LLC | $18.91 | 1 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $17.29 | 1 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $14.52 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $217.25 | 10 | Otsuka America Pharmaceutical, Inc. ($149.71) |
| 2023 | $14.52 | 1 | Janssen Pharmaceuticals, Inc ($14.52) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $18.91 | General |
| Category: PSYCHIATRY | ||||||
| 12/10/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $25.54 | General |
| Category: PSYCHIATRY | ||||||
| 11/19/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug), ABILIFY ASIMTUFII | Food and Beverage | In-kind items and services | $28.72 | General |
| Category: PSYCHIATRY | ||||||
| 11/05/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $31.34 | General |
| Category: CNS | ||||||
| 09/17/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $12.39 | General |
| Category: PSYCHIATRY | ||||||
| 09/10/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: Neurology | ||||||
| 07/02/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $13.91 | General |
| Category: PSYCHIATRY | ||||||
| 04/16/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug) | Food and Beverage | In-kind items and services | $27.75 | General |
| Category: PSYCHIATRY | ||||||
| 03/19/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug), ABILIFY ASIMTUFII | Food and Beverage | In-kind items and services | $26.63 | General |
| Category: PSYCHIATRY | ||||||
| 01/30/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug) | Food and Beverage | In-kind items and services | $14.77 | General |
| Category: PSYCHIATRY | ||||||
| 11/04/2023 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: Neuroscience | ||||||
About Ann Morrison, FNP
Ann Morrison, FNP is a Community Health Worker healthcare provider based in Palo Alto, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/13/2008. The National Provider Identifier (NPI) number assigned to this provider is 1740436492.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ann Morrison, FNP has received a total of $231.77 in payments from pharmaceutical and medical device companies, with $217.25 received in 2024. These payments were reported across 11 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($231.77).
Practice Information
- Specialty Community Health Worker
- Other Specialties Family
- Location Palo Alto, CA
- Active Since 08/13/2008
- Last Updated 04/16/2010
- Taxonomy Code 172V00000X
- Entity Type Individual
- NPI Number 1740436492
Products in Payments
- REXULTI (Drug) $70.75
- ABILIFY MAINTENA (Drug) $55.35
- ABILIFY ASIMTUFII (Drug) $42.52
- LYBALVI (Drug) $31.34
- UZEDY (Drug) $17.29
- SPRAVATO (Drug) $14.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.